Cytoreductive surgery combined with HIPEC in newly diagnosed and recurrent ovarian cancer
Journal Title: European Journal of Gynaecological Oncology - Year 2019, Vol 40, Issue 1
Abstract
Objective: Perioperative intraperitoneal chemotherapy after cytoreductive surgery is used in ovarian cancer treatment. The purpose of the study is the evaluation of the effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as upfront treatment in advanced ovarian cancer. Materials and Methods: Prospective observational study of 166 women that underwent 189 cytoreductive operations for advanced ovarian cancer and in 55 of them HIPEC was used as upfront treatment. Clinical indicators were correlated to morbidity, hospital mortality, survival, and recurrences. Results: HIPEC as upfront treatment was found to be related to recurrence (p = 0.001) but not to overall survival. The prognostic variables of survival were the performance status, the completeness of cytoreduction, and the use of HIPEC (p < 0.001). The prognostic variables of recurrence were the degree of differentiation, and systemic chemotherapy (p = 0.05). Conclusion: HIPEC as upfront treatment after cytoreductive surgery may be another promising treatment strategy in patients with epithelial ovarian cancer. Prospective randomized trials are required.
Authors and Affiliations
A. A. K. Tentes, T. B. Palaskas, K. Stamou, C. E. Stoforos, N. Pallas, C. Karamveri, D. Kyziridis, V. Kyriakopoulos
Keywords
Related Articles
- EP ID EP626319
- DOI 10.12892/ejgo4248.2019
- Views 83
- Downloads 0
Immunohistochemical analysis of IQGAP2 in ovarian cancer
IQ motif-containing GTPase-activating protein 2 (IQGAP2) was regarded as a tumor suppressor in some cancers, but its expression pattern in various histological subtypes of ovarian cancer has not been investigated. Immuno...
Expression of FOXA1 in breast cancer and the significance
Objective: The aim of this study to examine the expression of FOXA1, ER, and PR in breast cancer and investigate the association between FOXA1 expression and clinical parameters. Materials and Methods: One hundred one ca...
The pleiotropic factor Y-box binding protein-1 enhances the anti-proliferative efficacy of 4-hydroxytamoxifen and fulvestrant on breast cancer cells in vitro
Purpose of investigation: The pleiotropic factor Y-box binding protein-1 (YB-1) is clinically correlated with breast cancer patients’ poor outcome. Due to the intereference of YB-1 with the estrogen receptor, the authors...
Survival rate and complications after different types of pelvic exenteration for gynecological cancer
Pelvic exenteration (PE) is an operative method for one-moment removal of pelvic organs, including reproductive tract, bladder, and rectosidgmoid. It is most commonly indicated in gynecologic oncology for treatment of lo...
Taraxacum officinale extract induces antitumorigenic effects in ovarian carcinoma cell lines
Purpose of Investigation: Patients suffering from ovarian cancer often use mistletoe preparations in combination with Taraxacum officinale (dandelion) extracts as supplementary therapy to conventional medicine. However,...